

06/22/00  
JC803 U.S. PTO

BOX PATENT APPLICATION  
Attorney Docket No. 24286

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kinneret SAVITZKY  
Amir TOPORIK  
Sharon BITON

JC858 U.S. PTO  
09/599400  
06/22/00

Serial No. NOT YET ASSIGNED

Filed: June 22, 2000

For: **VARIANT OF TNF-RECEPTOR**

TRANSMITTAL LETTER

The Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark  
Office is the following:

- (1) Transmittal Letter
- (2) PTO Form-1082
- (3) 68 page English Language Application consisting of:
  - 45 pages Textual Specification
  - 5 pages of 30 claims
  - 1 page containing the Abstract of the Disclosure
  - 5 sheets drawings
  - 12 pages sequence listing
- (4) Unexecuted Declaration and Power of Attorney
- (5) Preliminary Amendment
- (6) Postcard for early notification of serial number.
- (7) *Computer Readable Form of Sequence Listing*

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

By: *Gary M. Nath*

Gary M. Nath  
Registration No. 26,965  
Customer No. 20529

Date: June 22, 2000  
NATH & ASSOCIATES PLLC  
1030<sup>th</sup> 15<sup>TH</sup> Street, NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005  
GMN/dd:APPL.trans

# NATH & ASSOCIATES PLLC

Attorneys at Law

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005-1503

TELEPHONE (202) 775-8383

(202) 775-9393

FACSIMILE (202) 775-8396

(202) 822-9409

E-Mail: [ip@nathlaw.com](mailto:ip@nathlaw.com)

Web: [www.nathlaw.com](http://www.nathlaw.com)

Gary M. Nath (DC, NJ)

Harold L. Novick (DC, MD)

Todd L. Juneau (DC, IL)

Irvin A. Lavine (DC), Retired\*

Donald M. Sandler (MD), Retired\*

Patent, Trademark and Copyright Causes

Unfair Competition, Trade Secrets,

Licensing and Litigation

\*Practice limited to Matters and Proceedings

before Federal Courts and Agencies; not Admitted  
in DC

Michelle L. Hartland (VA)\*

Lee C. Heiman (CA)\*

Jerald L. Meyer (VA)\*

Paul A. Sacher (MD)\*

David R. Murphy (VA)\*

Marvin C. Berkowitz (GA)\*

Tanya E. Jankovic (MD)\*

Joshua B. Goldberg (VA)\*

Nahied K. Usman (VA)\*

Alvin E. Tanenholz \*\*

Charles D. Niebylski, Ph.D.\*\*

Deborah H. Yellin\*\*

Roger C. Hahn\*\*

\*\* Registered Patent Agent: not Admitted in DC

## FORM PTO-1082

### TRANSMITTAL FOR NEW U.S. PATENT APPLICATION

Assistant Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Re: New U.S. Patent Application  
For: **VARIANT OF TNF-RECEPTOR**  
Inventor(s): Kinneret SAVITZKY  
Amir TOPORIK  
Sharon BITON  
Attorney Docket: 24286

Sir:

Attached hereto is the application identified above, including:

68 Pages Application Consisting of:  
45 Pages of Textual Specification  
5 Pages of 30 Claims  
1 Abstract of the Disclosure  
5 Sheets of drawings  
12 Pages Sequence Listing.  
   Executed Inventor's Declaration  
X Unexecuted Inventor's Declaration  
   Small Entity Statement  
   Assignment and cover sheet

The Government filing fee\* is calculated as follows:  
Total Claims . . . . . 37 - 20 = 17 x \$18.00 = \$306.00  
Independent Claims . . . . .    1 - 3 = 0 x \$78.00 = \$0.00  
Base Fee . . . . . \$690.00  
Multiple Dependent Claim Fee (\$260.00) . . . . . \$0.00  
Subtotal . . . . . \$996.00

**TOTAL FILING FEE\***  
**(accounting for possible small entity status) . . . . . \$498.00**

003300 "004550"

X \*Reduced by one-half, as applicant(s) is/are a "small entity".  
A Declaration Claiming Small Entity Status:

\_\_\_ is submitted herewith;

X will be filed at a later date.

X Foreign priority is claimed under 35 U.S.C. § 119 from ISRAEL  
Patent Application(s) No. 130608 dated 23 June 1999.

X Priority document(s) will be submitted at a later date.

\_\_\_ Priority document(s) is/are submitted herewith.

X Executed Declaration(s) will be submitted at a later date  
pursuant to 37 CFR § 1.41 and § 1.53, with an appropriate  
surcharge under 37 CFR § 1.16(e).

X Formal drawing(s) is/are attached.

\_\_\_ Formal drawing(s) will be submitted at a later date.

\_\_\_ Assignment document(s) is/are submitted herewith; the recorda-  
tion fee of \$40.00 per document is enclosed herewith.

X Assignment document will be submitted at a later date.


\_\_\_ A Verified Translation will be submitted at a later date.

\_\_\_ No payment is enclosed at this time. Full payment will be  
made when the executed Declaration is submitted.

\_\_\_ Submitted herewith is a check in the amount of \$\_\_\_\_.

Respectfully submitted,

**NATH & ASSOCIATES PLLC**

  
\_\_\_\_\_  
Gary M. Nath  
Registration No. 26,965  
Customer No. 20529

Date: June 22, 2000  
NATH & ASSOCIATES PLLC  
1030 15<sup>TH</sup> Street NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005  
(202)-775-8383  
GMN/dd (1082)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kinneret SAVITZKY  
Amir TOPORIK  
Sharon BITON

Serial No. NOT YET ASSIGNED

Filed: June 22, 2000

For: **VARIANT OF TNF-RECEPTOR**

PRELIMINARY AMENDMENT

The Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Before calculating the filing fee for the above identified application, please enter the following amendments:

IN THE CLAIMS:

Please amend claims 5-9, 11-12, 14, 16-17, 20 and 25-29 as follows:

Claim 5, line 2, delete "or 4".

Claim 6, line 2, delete "or 4".

Claim 7, line 2, delete "Claims 3 or 4" and insert in lieu thereof --Claim 3--.

Claim 8, line 3, delete "Claims 3 or 4" and insert in lieu thereof --Claim 3--.

Claim 9, line 2, delete "or 5".

Claim 11, line 1, delete "or 10".

12. (Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient [an agent selected from the group consisting of:

(i)] the expression vector of Claim 9[; and  
(ii) any one of the amino acid sequences of Claims 3 or 4].

14. (Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient [an agent selected from the group consisting of:

- (i)] any one of the nucleic acid sequences of Claim 2[;
- (ii) the expression vector of Claim 10; and
- (iii) the purified antibody of Claim 6 or 7].

Claim 16, line 4, delete "or 2".

Claim 17, line 4, delete "or 2".

Claim 20, line 1, delete "any of Claims 16 to 19" and insert in lieu thereof, --Claim 16--.

Claim 25, line 1, delete "or 4".

Claim 26, line 1, delete "or 4".

27. (Amended) A method for detecting any one of the amino acid sequences of [Claims 3 or 4] SEQ ID NO:9 to SEQ ID NO:16 in a biological sample, comprising the steps of:

- (a) contacting with said biological sample the antibody of Claim 6 [or 7], thereby forming an antibody-antigen complex; and
  - (b) detecting said antibody-antigen complex
- wherein the presence of said antibody-antigen complex correlates with the presence of the desired amino acid in said biological sample.

28. (Amended) A method for detecting the level of the amino acid sequence of any one of [Claims 3 or 4] SEQ ID NO:9 to SEQ ID

NO:16 in a biological sample, comprising the steps of:

- (a) contacting with said biological sample the antibody of Claim 6 [or 7], thereby forming an antibody-antigen complex; and
- (b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.

29. (Amended) A method for determining the ratio between the level of any one of the amino acid sequences of [Claims 3 or 4] SEQ ID NO:9 to SEQ ID NO:16 of variant TNFR present in a first biological sample and the level of the original TNFR amino acid sequences from which they were varied by alternative splicing, present in a second biological sample, the method comprising:

(a) determining the level of the amino acid sequences of [Claims 3 or 4] SEQ ID NO:9 to SEQ ID NO:16 into a first sample by the method of Claim 28;

(b) determining the level of the original TNFR amino acid sequence in the second sample; and

[(d)] (c) comparing the level obtained in (a) and (b) to give said ratio.

Please add the following newly submitted claims:

--31. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient any one of the amino acid sequences of Claim 3.

32. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient any one of the amino acid sequences of Claim 4.

33. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient the expression

vector of Claim 10.

34. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient the purified antibody of Claim 6.

35. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient the purified antibody of Claim 7.

36. A method for detecting any one of the amino acid sequences of SEQ ID NO:9 to SEQ ID NO:16 in a biological sample, comprising the steps of:

(a) contacting with said biological sample the antibody of Claim 7, thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex wherein the presence of said antibody-antigen complex correlates with the presence of the desired amino acid in said biological sample.

37. A method for detecting the level of the amino acid sequence of any one of SEQ ID NO:9 to SEQ ID NO:16 in a biological sample, comprising the steps of:

(a) contacting with said biological sample the antibody of Claim 7, thereby forming an antibody-antigen complex; and

(b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.--

**REMARKS**


The above amendments have been made to remove multiple dependencies from the claims. The newly submitted claims have

been added to claim the material removed by removing the multiple dependencies. Applicants respectfully submit that no new matter within the meaning of 35 U.S.C. 132 is added by the claim amendments and newly submitted claims.

Respectfully submitted,

**NATH & ASSOCIATES PLLC**

By: \_\_\_\_\_

  
Gary M. Nath  
Registration No. 26,965  
Jerald L. Meyer  
Registration No. 41,194  
Customer No. 20529

Date: June 22, 2000  
NATH & ASSOCIATES PLLC  
1030<sup>th</sup> Street, NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005  
GMN/dd::AMENDpreml



## VARIANT OF TNF-RECEPTOR

### FIELD OF THE INVENTION

The present invention concerns novel nucleic acid sequences, vectors and host cells containing them, amino acid sequences encoded by said sequences, and antibodies reactive with said amino acid sequences, as well as pharmaceutical compositions comprising any one the above. The present invention further concerns methods for screening for candidate agonists or antagonists utilizing said amino acid sequences.

### BACKGROUND OF THE INVENTION

Tumor necrosis factor (TNF) is a powerful cytokine which is involved in the immune immune and pro-inflammatory response. The TNF receptors (TNF-R1 and TNF-R2) are the sole mediators of the TNF signaling. The receptors consist of a disulfide-rich domain which recognizes TNF, a *trans* membrane helix, and a cytoplasmic domain. Signaling occurs when a TNF- trimer binds to two or three receptors in an extracellular complex which permits aggregation and activity of the cytoplasmic domain. The complex is then endocytosed, where it disassociates at low pH. There are two different proteins that serve as major receptors of TNF $\alpha$ , one associated with myeloid cells and one associated with epithelial cells. The TNF-A and TNF-B receptors are of different sizes and are expressed differentially in different cell lines. TNF-A Receptor, referred by some as TNF-R55, is the smaller of the two receptors. Whereas the extracellular domains of the two receptors are strikingly similar in structure, their intracellular domains appear to be unrelated. Southern blotting of human genomic DNA using the cDNA of the two receptors as probes, indicates that each is encoded by a single gene.

There is evidence suggesting that there exist soluble forms of TNF receptors which are structurally identical to the extracellular cytokine binding domains of these receptors, and it has been postulated that these soluble forms are the result of proteolytic activity on the full receptors. There have been  
5 suggestions that determination of the level soluble TNF receptor, especially R55, might enable to differentiate between rheumatoid arthritis and osteoarthritis and gout. In addition, there have been some data which proves that there is enhanced expression and shedding of tumor necrosis factor receptors from mononucleo- leukocytes in human heart failures.

10

## GLOSSARY

In the following description and claims use will be made, at times, with a variety of terms, and the meaning of such terms as they should be construed in accordance with the invention is as follows:

15

***"TNFR Variant nucleic acid sequence"*** – the sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 8, sequences having at least 90% identity (see below) to said sequence and *fragments* (see below) of the above sequences of least 20 b.p. long. These sequences are sequences coding for a novel, naturally occurring,  
20 alternative splice variants of the native and known TNFR, depicted in the GenBank as HUMTNFRB under Accession Number M58286 M33480 which is the human 55 kd human tumor necrosis factor receptor. It should be emphasized that the novel variants of the present invention are naturally occurring sequences resulting from alternative splicing of the TNFR gene and not merely truncated, mutated or  
25 fragmented forms of the gene.

The differences between the proteins coded by each of the amino acid sequence and the original protein are summarized in Table 1 below.

***"TNFR Variant product – also referred at times as the "TNFR variant protein"***  
30 or ***"TNFR variant polypeptide"*** – is an amino acid sequence encoded by the TNFR

variant nucleic acid sequences which is a naturally occurring mRNA sequence obtained as a result of alternative splicing. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having *chemically modified* amino acids (see below) such as a glycopeptide or glycoprotein. The TNFR variant products are shown in any one of SEQ ID NO: 9 to SEQ ID NO: 16. The term also includes *homologies* (see below) of said sequences in which one or more amino acids has been added, deleted, *substituted* (see below) or *chemically modified* (see below) as well as *fragments* (see below) of this sequence having at least 10 amino acids.

10

**"Nucleic acid sequence"** - a sequence composed of DNA nucleotides, RNA nucleotides or a combination of both types and may includes natural nucleotides, chemically modified nucleotides and synthetic nucleotides.

15 **"Amino acid sequence"** - a sequence composed of any one of the 20 naturally appearing amino acids, amino acids which have been *chemically modified* (see below), or composed of synthetic amino acids.

**"Fragment of TNFR variant nucleic acid sequence"** - novel short stretch of nucleic acid sequences of at least 20 b.p., which does not appear as a continuous stretch in the *original TNFR sequence* (see below) and is part of sequence depicted in SEQ ID NO: 1 to 8. In Table 1 below there is a summary of amino acids common between each variant and the original sequence and those which differ from the two. Fragments of the invention are those which comprise the sequences coding for the amino acids by which the variant differs from the original sequence.

**"Fragments of TNFR variant products"** - novel amino acid sequences coded by the *"fragment of TNFR variant nucleic acid sequence"* defined above. The

fragments include sequences specified in Table 1 below as having different amino acids.

5 **"Homologues of variants"** - amino acid sequences of variants in which one or more amino acids has been added, deleted or replaced. The addition, deletion or replacement should be in regions or adjacent to regions where the TNFR variant differs from the *original TNFR sequence* (for those sequences see Table 1 below).

10 **"Conservative substitution"** - refers to the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. [Six  
15 general classes of amino acid side chains have been categorized and include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class III residue such as Asn, Gln, or Glu, is a conservative substitution.

20 **"Non-conservative substitution"** - refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, Glu, or Gln.

25 **"Chemically modified"** - when referring to the product of the invention, means a product (protein) where at least one of its amino acid residues is modified either by natural processes, such as processing or other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the numerous known modifications typical, but not exclusive examples include:  
30 acetylation, acylation, amidation, ADP-ribosylation, glycosylation, GPI anchor

formation, covalent attachment of a lipid or lipid derivative, methylation, myristylation, pegylation, prenylation, phosphorylation, ubiquitination, or any similar process.

- 5 *"Biologically active"* - refers to the variant product having some sort of biological activity, for example, some physiologically measurable effect on target cells, molecules or tissues.

*"Immunologically active"* defines the capability of a natural, recombinant or  
10 synthetic variant product, or any fragment thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. Thus, for example, an immunologically active fragment of variant product denotes a fragment which retains some or all of the immunological properties of the variant product, e.g. can bind specific anti-variant product antibodies or which  
15 can elicit an immune response which will generate such antibodies or cause proliferation of specific immune cells which produce variant.

*"Optimal alignment"* - is defined as an alignment giving the highest percent identity score. Such alignment can be performed using a variety of commercially  
20 available sequence analysis programs, such as the local alignment program LALIGN using a ktup of 1, default parameters and the default PAM. A preferred alignment is the one performed using the CLUSTAL-W program from MacVector (TM), operated with an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM similarity matrix. If a gap needs to be inserted  
25 into a first sequence to optimally align it with a second sequence, the percent identity is calculated using only the residues that are paired with a corresponding amino acid residue (i.e., the calculation does not consider residues in the second sequences that are in the "gap" of the first sequence). In case of alignments of known gene sequences with that of the new variant, the optimal alignment  
30 invariably included aligning the identical parts of both sequences together, then

keeping apart and unaligned the sections of the sequences that differ one from the other.

*"Having at least 90% identity"* - with respect to two amino acid or nucleic acid sequence sequences, refers to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 90% amino acid sequence identity means that 90% of the amino acids in two or more optimally aligned polypeptide sequences are identical, however this definition explicitly excludes sequences which are 100% identical with the original sequence from which the variant of the invention was varied.

*"Isolated nucleic acid molecule having an variant nucleic acid sequence"* - is a nucleic acid molecule that includes the coding variant nucleic acid sequence. Said isolated nucleic acid molecule may include the variant nucleic acid sequence as an independent insert; may include the variant nucleic acid sequence fused to an additional coding sequences, encoding together a fusion protein in which the variant coding sequence is the dominant coding sequence (for example, the additional coding sequence may code for a signal peptide); the variant nucleic acid sequence may be in combination with non-coding sequences, e.g., introns or control elements, such as promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host; or may be a vector in which the variant protein coding sequence is a heterologous.

*"Expression vector"* - refers to vectors that have the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaryotic expression vectors are known and/or commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art.

**"Deletion"** - is a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

**"Insertion" or "addition"** - is that change in a nucleotide or amino acid  
5 sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring sequence.

**"Substitution"** - replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. As regards amino acid  
10 sequences the substitution may be conservative or non-conservative.

**"Antibody"** - refers to IgG, IgM, IgD, IgA, and IgG antibody. The definition includes polyclonal antibodies or monoclonal antibodies. This term refers to whole antibodies or fragments of the antibodies comprising the antigen-binding  
15 domain of the anti-variant product antibodies, e.g. antibodies without the Fc portion, single chain antibodies, fragments consisting of essentially only the variable, antigen-binding domain of the antibody, etc.

**"Agonist"** - as used herein, refers to a molecule which activates, in a similar  
20 manner to the natural TNF ligand and the TNFR variants of the invention. Agonists may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which can bind to and activate the variant product.

**"Antagonists"** - refers to a molecule which inhibits the activity of the TNFR  
25 variant of the invention. This may be done by any mechanism known to antagonists or inhibit biological receptor such as block of the receptor, block of active site of the ligand, competition on binding site in ligand, enhancement of degradation, etc. Antagonist may be polypeptides, nucleic acids, carbohydrates,

lipids, or derivatives thereof, or any other molecules which bind to and modulate the activity of said product.

*"Treating a disease"* - refers to administering a therapeutic substance effective  
5 to ameliorate symptoms associated with a disease, to lessen the severity or cure the disease, or to prevent the disease from occurring.

*"Detection"* - refers to a method of detection of a disease, disorder, pathological or normal condition. This term may refer to detection of a predisposition to a  
10 disease as well as for establishing the prognosis of the patient by determining the severity of the disease.

*"Probe"* - the variant nucleic acid sequence, or a sequence complementary therewith, when used to detect presence of other similar sequences in a sample.  
15 The detection is carried out by identification of hybridization complexes between the probe and the assayed sequence. The probe may be attached to a solid support or to a detectable label.

*"Original TNFR sequence"* - the amino acid or nucleic acid sequence from  
20 which the TNFR variants of the invention have been varied as a result of alternative slicing. The original sequence is the sequence of the human 55kd human necrosis factor receptor depicted as HUMTNFRB in the GenBank under Accession Number M58286 M33980.

## SUMMARY OF THE INVENTION

25 The present invention is based on the finding of eight novel, naturally occurring splice variants of the tumor necrosis factor receptor (TNFR) 55kd, which are naturally occurring sequences obtained by alternative splicing of the known TNFR genes depicted as HUMTNFRB in the GenBank under Accession Number M58286 M33480. The novel splice variants of the invention are not merely



truncated forms, fragments or mutations of known gene, but rather novel sequences which naturally occur within the body of individuals.

The term "*alternative splicing*" in the context of the present invention and claims refers to: intron inclusion, exon exclusion, addition or deletion of terminal  
5 sequences in the variant as compared to the original sequences. Detailed explanation of the differences between the variants of the invention of the original sequence may be found in Table 1 present in the "*Detailed Description*" part of the specification.

The novel TNFR variant products of the invention may have the same  
10 physiological activity as the original TNFR from which they are varied (although perhaps at a different level); may have an opposite physiological activity from the activity featured by the original peptide from which they are varied; may have a completely different, unrelated activity to the activity of the original from which they are varied; or alternatively may have no activity at all and this may lead to  
15 various diseases or pathological conditions. In addition, the variants may be different from the original sequence by properties not related to physiological activity such as: tissue distribution; temporal expression patterns; affinity to ligands, agonists, antagonists; clearance and degradation rates, manner of up or down regulation, etc.

20 The product of SEQ ID NO: 9 and No. 13 may be a soluble receptor capable of binding to TNF. The product of SEQ ID NOS: 10, 11 may be capable of activating downstream signals which are different than those activated through the original receptor. SEQ ID NO: 16 may be capable of various intracellular dominant negative effects. SEQ ID NOS: 10 and 13 may also have a dominant negative  
25 effect.

The novel TNFR variants may also serve for detection purposes, i.e. their presence or level may be indicative of a disease, disorder, pathological or normal condition involving TNF receptor such as inflammatory diseases (both infective and autoimmune), cytokine-involved pathological conditions, apoptosis (whether  
30 lack of such as in cancer or too much of such as in degenerative diseases), cancer,

wasting, etc. Alternatively the ratio between the level variants and the level original TNFR peptide from which they were varied, or the ratio to other variants may be indicative to such a disease, disorder, pathological or normal condition.

For example, for detectional purposes, it is possible to establish differential  
5 expression of the two variants in various tissues as compared to each other and as compared to the original TNFR sequence. One variant may be expressed mainly in one tissue, while the original TNFR sequence from which it has been varied, or the other variant may, be expressed mainly in another tissue. Understanding of the distribution of the two variants in various tissues may be helpful in basic research,  
10 for understanding the physiological function of the genes as well as may help in targeting pharmaceuticals or developing pharmaceuticals. In addition, understanding of this distribution may help tailor more specific medicaments as will be explained below.

The study of the variants may also be helpful to distinguish various stages in  
15 the life cycles of the same type of cells which may also be helpful for development of pharmaceuticals for various pathological conditions in which cell cycles is abnormal, notably cancer.

Thus the detection may by determination of the presence or the level of expression of the variant within a specific cell population, comprising said presence  
20 or level between various cell types in a tissue, between different tissues and between individuals.

Thus the present invention provides by its first aspect, a novel isolated nucleic acid molecule comprising or consisting of any one of the coding sequence SEQ ID NO: 1 to SEQ ID NO: 8, fragments of said coding sequence having at least  
25 20 nucleic acids (provided that said fragments are continuous stretches of nucleotides not present in the original TNFR sequence from which the variant was varied), or a molecule comprising a sequence having at least 90%, identity to SEQ ID NO:1 to SEQ ID NO:8.

The present invention further provides a protein or polypeptide comprising  
30 or consisting of an amino acid sequence encoded by any of the above nucleic acid

sequences, termed herein "*TNFR variant product*", for example, an amino acid sequence having the sequence as depicted in any one of SEQ ID NO:9 to SEQ ID NO:16, fragments of the above amino acid sequence having a length of at least 10 amino acids coded by the above fragments of the nucleic acid sequences, as well  
5 as homologues of the above amino acid sequences in which one or more of the amino acid residues has been substituted (by conservative or non-conservative substitution) added, deleted, or chemically modified.

The deletions, insertions and modifications should be in regions, or adjacent to regions, wherein the variant differs from the original sequence, and these regions  
10 are explained in detail in Table 1 below, in the "*Detailed Description*" part of the specification.

It should be appreciated that once a man versed in the art's attention is directed to the importance of a specific region, due to the fact that this region differs in the TNFR variant as compared to the original TNFR sequence, there is no  
15 problem in derivating said specific region by addition to it, deleting from it, or substituting some amino acids in it. Thus homologues of the TNFR variants which are derivated from the original TNFR by changes (deletion, addition, substitution) only in said region as well as in regions adjacent to it are also a part of the present invention. Generally, if the TNFR variant is distinguished from the original TNFR  
20 sequence by some sort of physiological activity, then the homolog is distinguished from the original TNFR sequence in essentially the same manner.

The present invention further provides nucleic acid molecule comprising or consisting of a sequence which encodes the above amino acid sequences, (including the fragments and homologues of the amino acid sequences). Due to the  
25 degenerative nature of the genetic code, a plurality of alternative nucleic acid sequences, beyond those depicted in any one of SEQ ID NO:1 to SEQ ID NO:8, can code for the amino acid sequence of the invention. Those alternative nucleic acid sequences which code for the same amino acid sequences depicted in SEQ ID NO:9 to SEQ ID NO:16 are also an aspect of the of the present invention.

The present invention further provides expression vectors and cloning vectors comprising any of the above nucleic acid sequences, as well as host cells transfected by said vectors.

The present invention still further provides pharmaceutical compositions comprising, as an active ingredient, said nucleic acid molecules, said expression  
5 vectors, or said protein or polypeptide.

These pharmaceutical compositions are suitable for the treatment of diseases and pathological conditions, which can be ameliorated or cured by raising the level of any one of the variant products of the invention. Examples of such diseases will  
10 be specified hereinbelow.

By a second aspect, the present invention provides a nucleic acid molecule comprising or consisting of a non-coding sequence which is complementary to that of any one of SEQ ID NO:1 to SEQ ID NO:8, or complementary to a sequence having at least 90% identity to said sequence or a fragment of said two sequences  
15 (according to the above definition of fragment). The complementary sequence may be a DNA sequence which hybridizes with any one of SEQ of ID NO:1 to SEQ ID NO:8 or hybridizes to a portion of that sequence having a length sufficient to inhibit the transcription of the complementary sequence. The complementary sequence may be a DNA sequence which can be transcribed into an mRNA being  
20 an antisense to the mRNA transcribed from any one of SEQ ID NO:1 to SEQ ID NO:8 or into an mRNA which is an antisense to a fragment of the mRNA transcribed from any one of SEQ ID NO:1 to SEQ ID NO:8 which has a length sufficient to hybridize with the mRNA transcribed from SEQ ID NO: 1 to SEQ ID NO: 8, so as to inhibit its translation. The complementary sequence may also be the  
25 mRNA or the fragment of the mRNA itself.

The nucleic acids of the second aspect of the invention may be used for therapeutic or diagnostic applications for example as probes used for the detection of the TNFR variants of the invention. The presence of the TNFR variant transcript or the level of the variant transcript may be indicative of a multitude of diseases,  
30 disorders and various pathological as well as normal conditions. In addition, the

ratio of the level of the transcripts of the variants of the invention may also be compared to that of the transcripts of the original TNFR sequences from which they were varied, or to the level of transcript of each other, and said ratio may be indicative to a multitude of diseases, disorders and various pathological and normal conditions. Comparison may be aided by the fact that each of the variants of the invention differ from the original TNFR by a specific sequence as specified in Table 1 below.

The present invention also provides expression vectors comprising any one of the above defined complementary nucleic acid sequences and host cells transfected with said nucleic acid sequences or vectors, being complementary to those specified in the first aspect of the invention.

The invention also provides anti-variant product antibodies, namely antibodies directed against the TNFR variant product which specifically bind to said TNFR variant product. Said antibodies are useful both for diagnostic and therapeutic purposes. For example said antibodies may be as an active ingredient in a pharmaceutical composition as will be explained below.

By another alternative, the invention concerns antibodies termed "*distinguishing antibodies*" which are directed solely to the amino acid sequences which distinguishes the TNFR variant from the original TNFR amino acid sequence from which it has been varied by alternative splicing and a detailed comparison is detailed in Table 1 below.

The distinguishing antibodies may be used for detection purposes, i.e. to detect individuals, tissue, conditions (both pathological or physiological) wherein the TNFR variant sequence or original sequence are low or high (as compared to a normal control). The antibodies may also be used to distinguish conditions where the level, or ratio of the TNFR variants to original TNFR sequence is altered.

The distinguishing antibodies may also be used for therapeutical purposes, i.e., to neutralize only the TNFR variants product or only the product of the original TNFR sequence, as the case may be, without neutralizing the other.

The present invention also provides pharmaceutical compositions comprising, as an active ingredient, the nucleic acid molecules which comprise or consist of said complementary sequences, or of a vector comprising said complementary sequences. The pharmaceutical composition thus provides  
5 pharmaceutical compositions comprising, as an active ingredient, said anti-variant product antibodies.

The pharmaceutical compositions comprising said anti-variant product antibodies or the nucleic acid molecule comprising said complementary sequence, are suitable for the treatment of diseases and pathological conditions where a  
10 therapeutically beneficial effect may be achieved by neutralizing the variants (either at the transcript or product level) or decreasing the amount of the variant product or blocking its binding to its ligand, for example, by the neutralizing effect of the antibodies, or by the decrease of the effect of the antisense mRNA in decreasing expression level of the TNFR variant product.

15 The pharmaceutical compositions (in accordance with both aspects) and the detection methods (whether by utilizing detection in the level of mRNA or in the level of the protein) may be used for the treatment or detection, respectively, of conditions which involve TNF. In the pharmaceutical composition the activity of the variants of the invention may be by binding to free TNF, thus decreasing its  
20 level, by activating various intracellular signaling mechanisms, etc. or by a combination of several mechanisms.

Examples of conditions which can be treated (prevented, ameliorated or cured) or detected (detection of presence, detection of predisposition to, determination of prognosis) are: inflammatory conditions including those resulting  
25 from infectious agents (viruses, bacteria, protozoa) and those resulting from autoimmune conditions especially of the digestive tract, the CNC, or rheumatoid conditions; conditions associated with endotoxic shock; conditions associated with faulty apoptosis notably cancer; conditions associated with wasting - loss of weight (caused by cancer, AIDS, or various other conditions); multiple sclerosis and any  
30 other physiological condition involving TNF.

The variant of the invention may also be used for the screening or for tailoring medicaments with high specificity. By utilizing the variants it is possible to produce or screen for medicaments which neutralize or activate only one or more variants while not affecting the original receptor. Such medicaments may be highly specific in activity only in certain tissues or in manifesting their physiological activity only under certain conditions.

According to the third aspect of the invention the present invention provides methods for detecting the level of the transcript (mRNA) of said TNFR variants product in a body fluid sample, or in a specific tissue sample, for example by use of probes comprising or consisting of said coding sequences; as well as methods for detecting levels of expression of said product in tissue, e.g. by the use of antibodies capable of specifically reacting with the variant products of the invention. Detection of the level of the expression of the variant of the invention in particular as compared to that of the original sequence from which it was varied or compared to other variant sequences all varied from the same original sequence may be indicative of a plurality of physiological or pathological conditions.

The method, according to this latter aspect, for detection of a nucleic acid sequence which encodes the TNFR variant products in a biological sample, comprises the steps of:

- (a) providing a probe comprising at least one of the nucleic acid sequences defined above;
- (b) contacting the biological sample with said probe under conditions allowing hybridization of nucleic acid sequences thereby enabling formation of hybridization complexes;
- (c) detecting hybridization complexes, wherein the presence of the complex indicates the presence of nucleic acid sequence encoding the TNFR variant product in the biological sample.

The method as described above is qualitative, i.e. indicates whether the transcript is present in or absent from the sample. The method can also be quantitative, by determining the level of hybridization complexes and then

calibrating said levels to determining levels of transcripts of the desired variant in the sample.

Both qualitative and quantitative determination methods can be used for diagnostic, prognostic and therapy planning purposes.

5 By a preferred embodiment the probe is part of a nucleic acid chip used for detection purposes, i.e. the probe is a part of an array of probes each present in a known location on a solid support.

The nucleic acid sequence used in the above method may be a DNA sequence an RNA sequence, etc; it may be a coding or a sequence or a sequence  
10 complementary thereto (for respective detection of RNA transcripts or coding-DNA sequences). By quantization of the level of hybridization complexes and calibrating the quantified results it is possible also to detect the level of the transcript in the sample.

Methods for detecting mutations in the region coding for the TNFR variant  
15 product are also provided, which may be methods carried-out in a binary fashion, namely merely detecting whether there is any mismatches between the normal variant nucleic acid sequence of the invention and the one present in the sample, or carried-out by specifically detecting the nature and location of the mutation.

The present invention also concerns a method for detecting the TNFR  
20 variant product in a biological sample, comprising the steps of:

(a) contacting with said biological sample the antibody of the invention, thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex

wherein the presence of said antibody-antigen complex correlates with the  
25 presence of the TNFR variant product in said biological sample.

As indicated above, the method can be quantitized to determine the level or the amount of the TNFR variant in the sample, alone or in comparison to the level of the original TNFR amino acid sequence from which it was varied, and qualitative and quantitative results may be used for diagnostic, prognostic and  
30 therapy planning purposes.



By yet another aspect the invention also provides a method for identifying candidate compounds capable of binding to the variant product and modulating its activity (being either agonists or antagonists). The method includes:

- (i) providing a protein or polypeptide comprising an amino acid  
5 sequence substantially as depicted in any one of SEQ ID NO:1 or SEQ ID NO:2, or a fragment of such a sequence;
- (ii) contacting a candidate compound with said amino acid sequence;
- (iii) measuring the physiological effect of said candidate compound on  
the activity of the amino acid sequences and selecting those  
10 compounds which show a significant effect on said physiological activity.

The present invention also concerns compounds identified by the above methods described above, which compound may either be an agonist or antagonist of the TNFR variant product.

## 15 BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

Fig. 1 shows multiple alignment of the nucleic acid sequences SEQ ID  
20 NO:1 to SEQ ID NO:8 to each other and to the original TNFR sequences.

## DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The following is a table which summarizes each variant, the regimes which it is common to the original sequence and those that differ; regions lacking in variant and potential function.

Domain	Known protein HUMTNRB	SEQ ID 1	SEQ ID 2	SEQ ID 3	SEQ ID 4	SEQ ID 5	SEQ ID 6	SEQ ID 7	SEQ ID 8
No. of total amino acid residues	455	219	270	306	240	115	75	64	170
Common a.a. to original sequence		1-217	1-267	1-296	1-228	1-96	1-13, 14-52	1-16;	1-6; 292-455
Different a.a. compared to original sequence		2a.a at the C-terminus	3a.a at the C-terminus	10a.a. at the C-terminus	12a.a. at the C-terminus	19a.a. at the C-terminus	Insertion of 4a.a. in position 14; 19a.a. at the C-terminus	48a.a at the C-terminus	Deletion between 7-292
Signal	+	+	+	+	+	+	+	+	-
TNF binding protein 1	+	+	+	+	+	Partial	-	-	-
Extracellular	+	+	+	+	+	+	-	-	-
Transmembrane	+	-	+	+	+	-	-	-	-
Cytoplasmic	+	-	Short tail (38a.a)	Short tail (72a.a)	-	-	-	-	+
4 X TNFR - CYS	+	+	+	+	+	1 X TNFR - CYS	-	-	-
N-SMASE activation domain	+	-	-	-	-	-	-	-	+
Death domain	+	-	-	-	-	-	-	-	+
Potential function		Soluble Receptor	Activate different downstream signals; dominant negative	Activate different downstream signals	Dominant negative	Soluble Receptor	Small peptide	Small peptide	Plasmic protein; intracellular dominant negative

**Example I: TNFR variant nucleic acid sequence**

The nucleic acid sequences of the invention include nucleic acid sequences which encode TNFR variant product and fragments and analogs thereof. The nucleic acid sequences may alternatively be sequences  
5 complementary to the above coding sequence, or to a region of said coding sequence. The length of the complementary sequence is sufficient to avoid the expression of the coding sequence. The nucleic acid sequences may be in the form of RNA or in the form of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and genomic DNA. The DNA may be double-stranded  
10 or single-stranded, and if single-stranded may be the coding strand or the non-coding (anti-sense, complementary) strand. The nucleic acid sequences may also both include dNTPs, rNTPs as well as non naturally occurring sequences. The sequence may also be a part of a hybrid between an amino acid sequence and a nucleic acid sequence.

15 In a general embodiment, the nucleic acid sequence has at least 90%, identity with any one of the sequence identified as SEQ ID NO:1 to SEQ ID NO:8.

The nucleic acid sequences may include the coding sequence by itself. By another alternative the coding region may be in combination with additional  
20 coding sequences, such as those coding for fusion protein or signal peptides, in combination with non-coding sequences, such as introns and control elements, promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host, and/or in a vector or host environment in which the variant nucleic acid sequence is introduced as a  
25 heterologous sequence.

The nucleic acid sequences of the present invention may also have the product coding sequence fused in-frame to a marker sequence which allows for purification of the variant product. The marker sequence may be, for example, a hexahistidine tag to provide for purification of the mature polypeptide fused to  
30 the marker in the case of a bacterial host, or, the marker sequence may be a

hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., *et al. Cell* 37:767 (1984)).

Also included in the scope of the invention are fragments as defined above  
5 also referred to herein as oligonucleotides, typically having at least 20 bases, preferably 20-30 bases corresponding to a region of the coding-sequence nucleic acid sequence. The fragments may be used as probes, primers, and when complementary also as antisense agents, and the like, according to known methods.

10 As indicated above, the nucleic acid sequence may be substantially a depicted in any one of SEQ ID NO:1 to SEQ ID NO:8 or fragments thereof or sequences having at least 90% identity to the above sequence as explained above. Alternatively, due to the degenerative nature of the genetic code, the sequence may be a sequence coding for any one of the amino acid sequence of SEQ ID  
15 NO:9 to SEQ ID NO:16, or fragments or analogs of said amino acid sequence.

#### A. Preparation of nucleic acid sequences

The nucleic acid sequences may be obtained by screening cDNA libraries using oligonucleotide probes which can hybridize to or PCR-amplify nucleic acid  
20 sequences which encode the TNFR variant products disclosed above. cDNA libraries prepared from a variety of tissues are commercially available and procedures for screening and isolating cDNA clones are well-known to those of skill in the art. Such techniques are described in, for example, Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (2nd Edition), Cold Spring  
25 Harbor Press, Plainview, N.Y. and Ausubel FM *et al.* (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y.

The nucleic acid sequences may be extended to obtain upstream and downstream sequences such as promoters, regulatory elements, and 5' and 3' untranslated regions (UTRs). Extension of the available transcript sequence may  
30 be performed by numerous methods known to those of skill in the art, such as

PCR or primer extension (Sambrook *et al.*, *supra*), or by the RACE method using, for example, the Marathon RACE kit (Clontech, Cat. # K1802-1).

Alternatively, the technique of "restriction-site" PCR (Gobinda *et al.* *PCR Methods Applic.* 2:318-22, (1993)), which uses universal primers to retrieve  
 5 flanking sequence adjacent a known locus, may be employed. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate  
 10 RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. *et al.*, *Nucleic Acids Res.* 16:8186, (1988)). The primers may be designed using OLIGO(R) 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth, Minn.), or another  
 15 appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

20 Capture PCR (Lagerstrom, M. *et al.*, *PCR Methods Applic.* 1:111-19, (1991)) is a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into a flanking part of the DNA molecule  
 25 before PCR.

Another method which may be used to retrieve flanking sequences is that of Parker, J.D., *et al.*, *Nucleic Acids Res.*, 19:3055-60, (1991)). Additionally, one can use PCR, nested primers and PromoterFinder™ libraries to "walk in" genomic DNA (PromoterFinder™; Clontech, Palo Alto, CA). This process avoids the need  
 30 to screen libraries and is useful in finding intron/exon junctions. Preferred

libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes.

A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region.

The nucleic acid sequences and oligonucleotides of the invention can also be prepared by solid-phase methods, according to known synthetic methods. Typically, fragments of up to about 100 bases are individually synthesized, then joined to form continuous sequences up to several hundred bases.

All the variants of the invention were validated by PCR and cloned in pStBlue1 (Novagene) expression vectors.

**B. Use of TNFR variants nucleic acid sequence for the production of TNFR variant products**

In accordance with the present invention, nucleic acid sequences specified above may be used as recombinant DNA molecules that direct the expression of TNFR variant products.

As will be understood by those of skill in the art, it may be advantageous to produce TNFR variant product-encoding nucleotide sequences possessing codons other than those which appear in any one of SEQ ID NO:1 to SEQ ID NO:8 which are those which naturally occur in the human genome. Codons preferred by a particular prokaryotic or eukaryotic host (Murray, E. *et al. Nuc Acids Res.*, 17:477-508, (1989)) can be selected, for example, to increase the rate of variant product expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

The nucleic acid sequences of the present invention can be engineered in order to alter a TNFR variant product coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing

and/or expression of the product. For example, alterations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, to change codon preference, etc.

5       The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises  
10 regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are also described in Sambrook, *et al.*, (*supra*).

15       The present invention also relates to host cells which are genetically engineered with vectors of the invention, and the production of the product of the invention by recombinant techniques. Host cells are genetically engineered (i.e., transduced, transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may  
20 be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the expression of the variant nucleic acid sequence. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected  
25 for expression, and will be apparent to those skilled in the art.

      The nucleic acid sequences of the present invention may be included in any one of a variety of expression vectors for expressing a product. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast  
30 plasmids; vectors derived from combinations of plasmids and phage DNA, viral

DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host. The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate  
5 restriction endonuclease site(s) by procedures known in the art. Such procedures and related sub-cloning procedures are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate transcription control sequence (promoter) to direct mRNA synthesis.  
10 Examples of such promoters include: LTR or SV40 promoter, the *E.coli lac* or *trp* promoter, the phage lambda *PL* promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation, and a transcription terminator. The vector may also include  
15 appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E.coli*.

20 The vector containing the appropriate DNA sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. Examples of appropriate expression hosts include: bacterial cells, such as *E.coli*, *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells  
25 such as *Drosophila* and *Spodoptera Sf9*; animal cells such as CHO, COS, HEK 293 or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. The invention is not limited by the host cells employed.

In bacterial systems, a number of expression vectors may be selected  
30 depending upon the use intended for the TNFR variant product. For example,



when large quantities of TNFR variant product are needed for the induction of antibodies. vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, multifunctional *E.coli* cloning and expression vectors such as *Bluescript*(R) (Stratagene), in which the TNFR variant polypeptide coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced; *pIN* vectors (Van Heeke & Schuster *J. Biol. Chem.* **264**:5503-5509, (1989)); *pET* vectors (Novagen, Madison WI); and the like.

10 In the yeast *Saccharomyces cerevisiae* a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel *et al.* (*supra*) and Grant *et al.*, (*Methods in Enzymology* **153**:516-544, (1987)).

In cases where plant expression vectors are used, the expression of a sequence encoding variant product may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of *CaMV* (Brisson *et al.*, *Nature* **310**:511-514, (1984)) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu *et al.*, *EMBO J.*, **6**:307-311, (1987)). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi *et al.*, *EMBO J.* **3**:1671-1680, (1984); Broglie *et al.*, *Science* **224**:838-843, (1984)); or heat shock promoters (Winter J and Sinibaldi R.M., *Results Probl. Cell Differ.*, **17**:85-105, (1991)) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S. or Murry L.E. (1992) in McGraw Hill Yearbook of Science and Technology, McGraw Hill, New York, N.Y., pp 191-196; or Weissbach and Weissbach (1988) *Methods for Plant Molecular Biology*, Academic Press, New York, N.Y., pp 421-463.

TNFR variant product may also be expressed in an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used

as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The TNFR variant product coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of TNFR variant coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which variant protein is expressed (Smith *et al.*, *J. Virol.* 46:584, (1983); Engelhard, E.K. *et al.*, *Proc. Nat. Acad. Sci.* 91:3224-7, (1994)).

10 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a TNFR variant product coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing variant protein in infected host cells (Logan and Shenk, *Proc. Natl. Acad. Sci.* 81:3655-59, (1984). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a variant product coding sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where TNFR variant product coding sequence, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf, D. *et al.*,

20  
25  
30

(1994) *Results Probl. Cell Differ.*, 20:125-62, (1994); Bittner et al., *Methods in Enzymol* 153:516-544, (1987)).

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., and Battey, I. (1986) *Basic Methods in Molecular Biology*). Cell-free translation systems can also be employed to produce polypeptides using RNAs derived from the DNA constructs of the present invention.

A host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "pre-pro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express variant product may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the

introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M., *et al.*, *Cell* 11:223-32, (1977)) and adenine phosphoribosyltransferase (Lowy I., *et al.*, *Cell* 22:817-23, (1980)) genes which can be employed in *tk-* or *aprt-* cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* which confers resistance to methotrexate (Wigler M., *et al.*, *Proc. Natl. Acad. Sci.* 77:3567-70, (1980)); *npt*, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al.*, *J. Mol. Biol.*, 150:1-14, (1981)) and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman S.C. and R.C. Mulligan, *Proc. Natl. Acad. Sci.* 85:8047-51, (1988)). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate, GUS, and luciferase and its substrates, luciferin and ATP, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. *et al.*, *Methods Mol. Biol.*, 55:121-131, (1995)).

Host cells transformed with a nucleotide sequence encoding TNFR variant product may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The product produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing nucleic acid sequences encoding TNFR variant product can be designed with signal sequences which direct secretion of TNFR variant product through a prokaryotic or eukaryotic cell membrane.

The TNFR variant product may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow  
5 purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle, Wash.). The inclusion of a protease-cleavable polypeptide linker sequence between the purification domain and TNFR variant product is useful to facilitate purification.  
10 One such expression vector provides for expression of a fusion protein comprising a variant polypeptide fused to a polyhistidine region separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography, as described in Porath, *et al.*, *Protein Expression and Purification*, 3:263-281, (1992)) while the  
15 enterokinase cleavage site provides a means for isolating variant polypeptide from the fusion protein. *pGEX* vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g.,  
20 glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are  
25 cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods,  
30 which are well know to those skilled in the art.

The TNFR variant products can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

10

**C. Diagnostic applications utilizing nucleic acid sequences**

The nucleic acid sequences of the present invention may be used for a variety of diagnostic purposes. The nucleic acid sequences may be used to detect and quantitate expression of the TNFR variant in patient's cells, e.g. biopsied tissues, by detecting the presence of mRNA coding for the TNFR variants products. Alternatively, the assay may be used to detect soluble variant in the serum or blood, especially for detection of the variant of SEQ ID NO: 1 which is soluble. This assay typically involves obtaining total mRNA from the tissue serum or blood contacting the mRNA with a nucleic acid probe. The probe is a nucleic acid molecule of at least 20 nucleotides, preferably 20-30 nucleotides, capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding the TNFR variant product under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of variant. This assay can be used to distinguish between absence, presence, and excess expression of TNFR variants product and to monitor levels of variants expression during therapeutic intervention. In addition, the assay may be used to compare the levels of the TNFR variant of the invention to the levels of the original TNFR sequence from which it has been varied or to levels of other variants, which comparison may have some physiological meaning.

15  
20  
25  
30

The invention also contemplates the use of the nucleic acid sequences as a diagnostic tool for diseases resulting from inherited defective variant sequences, or diseases in which the ratio of the amount of the original TNFR sequence from which the TNFR variants was varied to the novel variants of the invention is altered. These sequences can be detected by comparing the sequences of the defective (i.e., mutant) TNFR variant coding region with that of a normal coding region. Association of the sequence coding for mutant TNFR variant product with abnormal variant product activity may be verified. In addition, sequences encoding mutant TNFR variant products can be inserted into a suitable vector for expression in a functional assay system (e.g., colorimetric assay, complementation experiments in a variant protein deficient strain of HEK293 cells) as yet another means to verify or identify mutations. Once mutant genes have been identified, one can then screen populations of interest for carriers of the mutant gene.

Individuals carrying mutations in the nucleic acid sequence of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including but not limited to such as from blood, urine, saliva, placenta, tissue biopsy and autopsy material. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki, *et al.*, *Nature* 324:163-166, (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid of the present invention can be used to identify and analyze mutations in the gene of the present invention. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype.

Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA of the invention or alternatively, radiolabeled antisense DNA sequences of the invention. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (e.g. Cotton, *et al.* *Proc. Natl. Acad. Sci. USA*,

85:4397-4401, (1985)), or by differences in melting temperatures. "*Molecular beacons*" (Kostrikis L.G. *et al.*, Science 279:1228-1229, (1998)), hairpin-shaped, single-stranded synthetic oligo- nucleotides containing probe sequences which are complementary to the nucleic acid of the present invention, may also be used  
5 to detect point mutations or other sequence changes as well as monitor expression levels of variant product. Such diagnostics would be particularly useful for prenatal testing.

Another method for detecting mutations uses two DNA probes which are designed to hybridize to adjacent regions of a target, with abutting bases, where  
10 the region of known or suspected mutation(s) is at or near the abutting bases. The two probes may be joined at the abutting bases, e.g., in the presence of a ligase enzyme, but only if both probes are correctly base paired in the region of probe junction. The presence or absence of mutations is then detectable by the presence or absence of ligated probe.

15 Also suitable for detecting mutations in the TNFR variant product coding sequence are oligonucleotide array methods based on sequencing by hybridization (SBH), as described, for example, in U.S. Patent No. 5,547,839. In a typical method, the DNA target analyte is hybridized with an array of oligonucleotides formed on a microchip. The sequence of the target can then be  
20 "read" from the pattern of target binding to the array.

#### **D. Gene mapping utilizing nucleic acid sequences**

The nucleic acid sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can  
25 hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present



invention is an important first step in correlating those sequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 20-30 bp) from the variant 5' cDNA. Computer analysis of the 3' untranslated region is used to rapidly select primers that do not span more than one exon in the genomic DNA, which would complicate the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids or using instead radiation hybrids are rapid procedures for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma *et al.*, *Human Chromosomes: a Manual of Basic Techniques*, (1988) Pergamon Press, New York.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in the OMIM database (Center for Medical Genetics, Johns Hopkins University, Baltimore, MD and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD). The OMIM gene map presents the cytogenetic map location of disease genes and other expressed genes. The OMIM database provides information on diseases associated with the chromosomal location. Such

5

Nucleic acid sequences of the invention may also be used for therapeutic purposes. Turning first to the second aspect of the invention (i.e. inhibition of expression of TNFR variant), expression of TNFR variant product may be modulated through antisense technology, which controls gene expression through hybridization of complementary nucleic acid sequences, i.e. antisense DNA or RNA, to the control, 5' or regulatory regions of the gene encoding variant product. For example, the 5' coding portion of the nucleic acid sequence sequence which codes for the product of the present invention is used to design an antisense oligonucleotide of from about 10 to 40 base pairs in length. Oligonucleotides derived from the transcription start site, e.g. between positions -10 and +10 from the start site, are preferred. An antisense DNA oligonucleotide is designed to be complementary to a region of the nucleic acid sequence involved in transcription (Lee *et al.*, *Nucl. Acids, Res.*, 6:3073, (1979); Cooney *et al.*, *Science* 241:456, (1988); and Dervan *et al.*, *Science* 251:1360, (1991)), thereby preventing transcription and the production of the variant products. An antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the variant products (Okano *J. Neurochem.* 56:560, (1991)). The antisense constructs can be delivered to cells by procedures known in the art such that the antisense RNA or DNA may be expressed *in vivo*. The antisense may be antisense mRNA or DNA sequence capable of coding such antisense mRNA. The antisense mRNA or the DNA coding thereof can be complementary to the full sequence of nucleic acid sequences coding for the TNFR variant protein or to a fragment of such a sequence which is sufficient to inhibit production of a protein product.

Turning now to the first aspect of the invention, i.e. expression of TNFR variant, expression of TNFR variant product may be increased by providing coding sequences for coding for said product under the control of suitable control elements ending its expression in the desired host.

5       The nucleic acid sequences of the invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The  
10       formulation should suit the mode of administration.

      The products of the invention as well as any activators and deactivators compounds (see below) which are polypeptides, may also be employed in accordance with the present invention by expression of such polypeptides *in vivo*, which is often referred to as "*gene therapy*." Cells from a patient may be  
15       engineered with a nucleic acid sequence (DNA or RNA) encoding a polypeptide *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

20       Similarly, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells *in vivo* and expression of the polypeptide *in vivo*. These and other methods for  
25       administering a product of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells *in vivo* after combination with a suitable delivery vehicle.

Retroviruses from which the retroviral plasmid vectors mentioned above may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the *PE501*, *PA317*, *psi-2*, *psi-AM*, *PA12*, *T19-14X*, *VT-19-17-H2*, *psi-CRE*, *psi-CRIP*, *GP+E-86*, *GP+envAml2*, and *DAN* cell lines as described in Miller (*Human Gene Therapy*, Vol. 1, pg. 5-14, (1990)). The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and  $\text{CaPO}_4$  precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

The genes introduced into cells may be placed under the control of inducible promoters, such as the radiation-inducible *Egr-1* promoter, (Maceri, H.J., et al., *Cancer Res.*, 56(19):4311 (1996)), to stimulate variant production or antisense inhibition in response to radiation, eg., radiation therapy for treating tumors.

### Example II. TNFR Variant product

The substantially purified TNFR variant product of the invention has been defined above as the product coded from the nucleic acid sequence of the invention. Preferably the amino acid sequence is an amino acid sequence having  
5 at least 90% identity to any one of the sequences identified as SEQ ID NO:1 to SEQ ID NO:16 provided that the amino acid sequence is not identical to that of the original sequence from which it has been varied. The protein or polypeptide may be in mature and/or modified form, also as defined above. Also contemplated are protein fragments having at least 10 contiguous amino acid  
10 residues, preferably at least 10-20 residues, derived from the TNFR variant product, as well as homologues as explained above.

The sequence variations are preferably those that are considered conserved substitutions, as defined above. Thus, for example, a protein with a sequence having at least 90% sequence identity with any of the products identified as SEQ  
15 ID NO:9 to 16, preferably by utilizing conserved substitutions as defined above is also part of the invention, and provided that it is not identical to the original peptide from which it has been varied. In a more specific embodiment, the protein has or contains any one of the sequence identified as SEQ ID NO:9 to 16. The TNFR variant product may be (i) one in which one or more of the amino acid  
20 residues in a sequence listed above are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue), or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the TNFR variant product is fused with another compound, such as a compound to increase the half-life of the protein (for  
25 example, polyethylene glycol (PEG)), or a moiety which serves as targeting means to direct the protein to its target tissue or target cell population (such as an antibody), or (iv) one in which additional amino acids are fused to the TNFR variant product. Such fragments, variants and derivatives are deemed to be within the scope of those skilled in the art from the teachings herein.

**A. Preparation of TNFR variants products**

Recombinant methods for producing and isolating the TNFR variant product, and fragments of the protein are described above.

In addition to recombinant production, fragments and portions of variant  
5 product may be produced by direct peptide synthesis using solid-phase techniques  
(cf. Stewart *et al.*, (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San  
Francisco; Merrifield J., *J. Am. Chem. Soc.*, **85**:2149-2154, (1963)). In vitro  
peptide synthesis may be performed using manual techniques or by automation.  
Automated synthesis may be achieved, for example, using Applied Biosystems  
10 431A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with  
the instructions provided by the manufacturer. Fragments of TNFR variant  
product may be chemically synthesized separately and combined using chemical  
methods to produce the full length molecule.

**15 B. Therapeutic uses and compositions utilizing the TNFR variants products**

The TNFR variants products of the invention is generally useful in treating  
diseases and disorders which are characterized by a lower than normal level of  
20 TNFR variant expression, and or diseases which can be cured or ameliorated by  
raising the level of the TNFR variant product, even if the level is normal.

TNFR variant products or fragments may be administered by any of a  
number of routes and methods designed to provide a consistent and predictable  
concentration of compound at the target organ or tissue. The product-containing  
25 compositions may be administered alone or in combination with other agents,  
such as stabilizing compounds, and/or in combination with other pharmaceutical  
agents such as drugs or hormones.

TNFR variant product-containing compositions may be administered by a  
number of routes including, but not limited to oral, intravenous, intramuscular,  
30 transdermal, subcutaneous, topical, sublingual, or rectal means as well as by nasal  
application. TNFR variant product-containing compositions may also be

002299-004550

administered via liposomes. Such administration routes and appropriate formulations are generally known to those of skill in the art.

The TNFR variant product can be given via intravenous or intraperitoneal injection. Similarly, the product may be injected to other localized regions of the body. The product may also be administered via nasal insufflation. Enteral  
5 administration is also possible. For such administration, the product should be formulated into an appropriate capsule or elixir for oral administration, or into a suppository for rectal administration.

The foregoing exemplary administration modes will likely require that the  
10 product be formulated into an appropriate carrier, including ointments, gels, suppositories. Appropriate formulations are well known to persons skilled in the art.

Dosage of the product will vary, depending upon the potency and therapeutic index of the particular polypeptide selected.

15 A therapeutic composition for use in the treatment method can include the product in a sterile injectable solution, the polypeptide in an oral delivery vehicle, the product in an aerosol suitable for nasal administration, or the product in a nebulized form, all prepared according to well known methods. Such compositions comprise a therapeutically effective amount of the compound, and a  
20 pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The product of the invention may also be used to modulate endothelial differentiation and proliferation as well as to modulate apoptosis either *ex vivo* or *in vitro*, for example, in cell cultures.

25

### **Example III. Screening methods for agonists and antagonists (inhibitors)**

The present invention also includes an assay for identifying molecules, such as synthetic drugs, antibodies, peptides, or other molecules, which have a  
30 modulating effect on the activity of the TNFR variant product, e.g. agonists or

antagonists (or inhibitors) of the TNFR variant products of the present invention. Such an assay comprises the steps of providing a TNFR variants products encoded by the nucleic acid sequences of the present invention, contacting the TNFR variant protein with one or more candidate molecules to determine the candidate molecules modulating effect on the activity of the variant product, and selecting from the molecules a candidate's molecule capable of modulating TNFR variant product physiological activity.

The TNFR variant product, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a cell membrane or located intracellularly. The formation of binding complexes, between variant product and the agent being tested, may be measured. Alternatively, the agonist or antagonist (inhibitor) may work by serving as agonist or antagonist, respectively, of the TNFR variant, or by binding the native ligand of the TNFR receptor, and their effect may be determined in connection with any of the above.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the TNFR variant product is described in detail by Geysen in PCT Application WO 84/03564, published on Sep. 13, 1984. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with the full TNFR variant product or with fragments of TNFR variant product and washed. Bound TNFR variant product is then detected by methods well known in the art. Substantially purified TNFR variant product can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

Antibodies to the variant product, as described in Example V below, may also be used in screening assays according to methods well known in the art. For



example, a "sandwich" assay may be performed, in which an anti-variant antibody is affixed to a solid surface such as a microtiter plate and variant product is added. Such an assay can be used to capture compounds which bind to the variant product. Alternatively, such an assay may be used to measure the ability of compounds to influence with the binding of the TNFR variant product to the variant receptor, and then select those compounds which effect the binding.

#### **Example V. Anti-variant antibodies/distinguishing antibodies**

##### **A. Synthesis**

In still another aspect of the invention, the purified variant product is used to produce anti-variant antibodies which have diagnostic and therapeutic uses related to the activity, distribution, and expression of the TNFR variants products. As indicated above, the antibodies may also be directed solely to amino acid sequences present in the TNFR variants but not present in the original TNFR sequence, or to sequences present only in the original TNFR sequence but not in the TNFR variant ("*distinguishing antibodies*").

Antibodies to the TNFR variant product or to the distinguishing sequence present only in the TNFR variant or only in the original TNFR sequence (the latter termed "*distinguishing antibodies*") may be generated by methods well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments and fragments produced by an Fab expression library. Antibodies, i.e., those which inhibit dimer formation, are especially preferred for therapeutic use.

A fragment of the TNFR variant product for antibody induction is not required to feature biological activity but has to feature immunological activity; however, the protein fragment or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids of the sequences specified in any one of SEQ ID NO:1 to SEQ ID NO:16 or in distinguishing sequences present only in the TNFR variant or only in the original TNFR sequence as

explained above. Preferably they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of TNFR variant protein amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to TNFR variant product.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with TNFR variant product or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are potentially useful human adjuvants.

Monoclonal antibodies to TNFR variant protein may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (*Nature* 256:495-497, (1975)), the human B-cell hybridoma technique (Kosbor *et al.*, *Immunol. Today* 4:72, (1983); Cote *et al.*, *Proc. Natl. Acad. Sci.* 80:2026-2030, (1983)) and the EBV-hybridoma technique (Cole, *et al.*, *Mol. Cell Biol.* 62:109-120, (1984)).

Techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can also be used (Morrison *et al.*, *Proc. Natl. Acad. Sci.* 81:6851-6855, (1984); Neuberger *et al.*, *Nature* 312:604-608, (1984); Takeda *et al.*, *Nature* 314:452-454, (1985)). Alternatively, techniques described for the production of single chain antibodies

(U.S. Pat. No. 4,946,778) can be adapted to produce single-chain antibodies specific for the variant protein.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or  
5 panels of highly specific binding reagents as disclosed in Orlandi *et al.* (*Proc. Natl. Acad. Sci.* **86**:3833-3837, 1989)), and Winter G and Milstein C., (*Nature* **349**:293-299, (1991)).

Antibody fragments which contain specific binding sites for the TNFR variant protein may also be generated. For example, such fragments include, but  
10 are not limited to, the F(ab')<sub>2</sub> fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse W.D. *et al.*, *Science*  
15 **256**:1275-1281, (1989)).

#### **B. Diagnostic applications of antibodies**

A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established  
20 specificities are well known in the art. Such immunoassays typically involve the formation of complexes between the TNFR variant product and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific variant product is preferred, but a  
25 competitive binding assay may also be employed. These assays are described in Maddox D.E., *et al.*, (*J. Exp. Med.* **158**:1211, (1983)).

Antibodies which specifically bind the TNFR variant product or distinguishing antibodies which bind to sequences which distinguish the TNFR variant from the original TNFR sequence (as explained above) are useful for the  
30 diagnosis of conditions or diseases characterized by expression of the novel

002299-046550

TNFR variant of the invention (where normally it is not expressed) by over or under expression of TNFR variants as well as for detection of diseases in which the proportion between the amount of the TNFR variants of the invention and the original TNFR sequence from which it varied is altered. Alternatively, such  
5 antibodies may be used in assays to monitor patients being treated with TNFR variants products, its agonists, or its antagonists. Diagnostic assays for variant protein include methods utilizing the antibody and a label to detect variant product in human body fluids or extracts of cells or tissues. The products and antibodies of the present invention may be used with or without modification.  
10 Frequently, the proteins and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known in the art.

A variety of protocols for measuring the TNFR variant product, using either polyclonal or monoclonal antibodies specific for the respective protein are  
15 known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescent activated cell sorting (FACS). As noted above, a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on TNFR variant product is preferred, but a competitive binding assay may be employed. These  
20 assays are described, among other places, in Maddox, *et al.* (*supra*). Such protocols provide a basis for diagnosing altered or abnormal levels of TNFR variant product expression. Normal or standard values for TNFR variant product expression are established by combining body fluids or cell extracts taken from normal subjects, preferably human, with antibodies to TNFR variants products  
25 under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by various methods, preferably by photometric methods. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease. Deviation between standard and subject  
30 values establishes the presence of disease state.

The antibody assays are useful to determine the level of TNFR variants products present in a body fluid sample, in order to determine whether it is being expressed at all, whether it is being overexpressed or underexpressed in the tissue, or as an indication of how TNFR variants levels of variable products are  
5 responding to drug treatment.

### C. Therapeutic uses of antibodies

In addition to their diagnostic use the antibodies may have a therapeutical utility in blocking or decreasing the activity of the TNFR variant product in  
10 pathological conditions where beneficial effect can be achieved by such a decrease. Again, distinguishing antibodies may be used to neutralize differentially either the TNFR variant or the original sequence as the case may be.

The antibody employed is preferably a humanized monoclonal antibody, or a human Mab produced by known globulin-gene library methods. The  
15 antibody is administered typically as a sterile solution by IV injection, although other parenteral routes may be suitable. Typically, the antibody is administered in an amount between about 1-15 mg/kg body weight of the subject. Treatment is continued, e.g., with dosing every 1-7 days, until a therapeutic improvement is seen.

20 Although the invention has been described with reference to specific methods and embodiments, it is appreciated that various modifications and changes may be made without departing from the invention.

**CLAIMS:**

1. An isolated nucleic acid sequence, of an alternative splicing variant of tumor necrosis factor receptor (TNFR), selected from the group consisting of:
  - (i) the nucleic acid sequence depicted in any one of SEQ ID NO: 1 to  
5 SEQ ID NO: 8;
  - (ii) nucleic acid sequences having at least 90% identity with the sequence of (i); and
  - (iii) fragments of (i) or (ii) of at least 20 b.p., provided that said fragment contains a sequence which is not present, as a continuous stretch of nucleotides, in  
10 the original nucleic acid sequence of TNFR from which the sequences of (i) have been varied by alternative splicing.
2. An isolated nucleic acid sequence complementary to the nucleic acid sequence of Claim 1.
3. An amino acid sequence selected from the group consisting of:
  - 15 (i) an amino acid sequence coded by the isolated nucleic acid sequence of alternative splice variants of Claim 1;
  - (ii) homologues of the amino acid sequences of (i) in which one or more amino acids has been added, deleted, replaced or chemically modified in the region, or adjacent to the region, where the amino acid sequences differs from the original  
20 amino acid sequence, coded by the original TNFR nucleic acid sequence from which the variant has been varied by alternative splicing.
4. An amino acid sequence according to Claim 3, as depicted in any one of SEQ ID NO:9 to SEQ ID NO:16.
5. An isolated nucleic acid sequence coding for any one of the amino acid  
25 sequences of Claim 3 or 4.
6. A purified antibody which binds specifically to any of the amino acid sequence of Claim 3 or 4.
7. A purified antibody which binds to an amino acid sequence which is present only in the alternative splice variant depicted in the amino acid of Claims 3 or 4,  
30 but is not present in the amino sequence of TNFR.

8. A purified antibody which binds to an amino acid sequence present in the amino acid sequence of TNFR which amino acid sequence is not present in the amino acid sequence of Claims 3 or 4.
9. An expression vector comprising any one of the nucleic acid sequences of Claim 1 or 5 and control elements for the expression of the nucleic acid sequence in a suitable host.
10. An expression vector comprising any one of the nucleic acid sequences of Claim 2, and control elements for the expression of the nucleic acid sequences in a suitable host.
- 10 11. A host cell transfected by the expression vector of Claim 9 or 10.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of:
  - (i) the expression vector of Claim 9; and
  - (ii) any one of the amino acid sequences of Claim 3 or 4.
- 15 13. A pharmaceutical composition according to Claim 12, for treatment of diseases which can be ameliorated, cured or prevented by raising the level of any one of the amino acid sequences depicted in SEQ ID NO:9 to SEQ ID NO:16.
14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of:
  - 20 (i) any one of the nucleic acid sequences of Claim 2;
  - (ii) the expression vector of Claim 10; and
  - (iii) the purified antibody of Claim 6 or 7.
- 15 15. A pharmaceutical composition according to Claim 14, for treatment of diseases which can be ameliorated, cured or prevented by lowering the level of any one of the amino acid sequences depicted in SEQ ID NO:9 to SEQ ID NO:16.
- 25 16. A method for detecting the presence of a variant nucleic acid sequence of TNFR in a biological sample, comprising the steps of:
  - (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of Claim 1 or 2; and
  - 30 (b) detecting said hybridization complex;

wherein the presence of said hybridization complex correlates with the presence of an variant nucleic acid sequence in the said biological sample.

17. A method for determining the level of variant nucleic acid sequences of TNFR in a biological sample comprising the steps of:

5 (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of Claim 1 or 2; and

(b) determining the amount of hybridization complexes and normalizing said amount to provide the level of the variant nucleic acid sequences in the sample.

10 18. A method for determining the ratio between the level of the nucleic acid sequence of a TNFR variant in a first biological sample and the level of the original TNFR sequence from which the variant has been varied by alternative splicing, in a second biological sample comprising:

(a) determining the level of the TNFR variant nucleic acid sequence in  
15 the first biological sample according to the method of Claim 17;

(b) determining the level of the TNFR original sequence in the second biological sample; and

(c) comprising the levels obtained in (a) and (b) to give said ratio.

19. A method according to Claim 18, wherein said first and said second  
20 biological samples are the same sample.

20. A method according to any of Claims 16 to 19, wherein the nucleic acid material of said biological sample are mRNA transcripts.

21. A method according to Claim 20, where the nucleic acid sequence is present in a nucleic acid chip.

25 22. A method for identifying candidate compounds capable of binding to the variant product and modulating its activity the method comprising:

(i) providing any one of the amino acid sequences as defined in Claim 3 or 4;

(ii) contacting a candidate compound with said amino acid sequence;



(iii) determining the effect of said candidate compound on the biological activity of said protein or polypeptide and selecting those compounds which show a significant effect on said biological activity.

23. A method according to Claim 22, wherein the compound is an agonist and  
5 the measured effect is increase in the biological activity.

24. A method according to Claim 22, wherein the compound is an antagonist and the effect is decrease in the biological activity.

25. An agonist of any one of the amino acid sequences of Claim 3 or 4.

26. An antagonist of any one of the amino acid sequences of Claims 3 or 4.

10 27. A method for detecting any one of the amino acid sequences of Claim 3 or 4 in a biological sample, comprising the steps of:

(a) contacting with said biological sample the antibody of Claim 6 or 7, thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex

15 wherein the presence of said antibody-antigen complex correlates with the presence of the desired amino acid in said biological sample.

28. A method for detecting the level of the amino acid sequence of any one of Claim 3 or 4 in a biological sample, comprising the steps of:

(a) contacting with said biological sample the antibody of Claim 6 or 7,  
20 thereby forming an antibody-antigen complex; and

(b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.

29. A method for determining the ratio between the level of any one of the  
25 amino acid sequences of Claims 3 or 4 of variant TNFR present in a first biological sample and the level of the original TNFR amino acid sequences from which they were varied by alternative splicing, present in a second biological sample, the method comprising:

(a) determining the level of the amino acid sequences of Claims 3 or 4  
30 into a first sample by the method of Claim 28;

(b) determining the level of the original TNFR amino acid sequence in the second sample; and

(d) comparing the level obtained in (a) and (b) to give said ratio.

30. A method according to Claim 29, wherein said first and said second  
5 biological samples are the same sample.

44 43 42 41 40 39 38 37 36 35 34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1





					150
	101				
HUMTNFRB	ECESGSFTAS	ENHLRHCLSC	SKCRKEMGQV	EISSCTVDRD	TVCGRKNQY
TNF_10co8	ECESGSFTAS	ENHLRHCLSC	SKCRKEMGQV	EISSCTVDRD	TVCGRKNQY
TNF_20co5	ECESGSFTAS	ENHLRHCLSC	SKCRKEMGQV	EISSCTVDRD	TVCGRKNQY
TNF_20co9	ECESGSFTAS	ENHLRHCLSC	SKCRKEMGQV	EISSCTVDRD	TVCGRKNQY
TNF_19co1	ECESGSFTAS	ENHLRHCLSC	SKCRKEMGQV	EISSCTVDRD	TVCGRKNQY
TNF_20co1	ECESGSFTAS	ENHMPVLGV	LTSKAARGPL	VRP*	~~~~~
TNF10-co9	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
TNF19co23	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	151				200
HUMTNFRB	RHYWSENLFQ	CFNCSLCLNG	TVHLSCQEKQ	NTVCTCHAGF	FLRENECVSC
TNF_10co8	RHYWSENLFQ	CFNCSLCLNG	TVHLSCQEKQ	NTVCTCHAGF	FLRENECVSC
TNF_20co5	RHYWSENLFQ	CFNCSLCLNG	TVHLSCQEKQ	NTVCTCHAGF	FLRENECVSC
TNF_20co9	RHYWSENLFQ	CFNCSLCLNG	TVHLSCQEKQ	NTVCTCHAGF	FLRENECVSC
TNF_19co1	RHYWSENLFQ	CFNCSLCLNG	TVHLSCQEKQ	NTVCTCHAGF	FLRENECVSC
TNF_20co1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
TNF10-co9	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
TNF19co23	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~

Fig. 1(Cont. <sup>1</sup>)

HUMTNFRB	201	SNCKKSLECT	KLCLPQIENV	KGTEDSGTTV	LLPLVIFFGL	250
TNF_10co8		SNCKKSLECT	KLCLPQIENV	KGTEDSGTTV	LLPLVRP*~	CLLSLLFI..
TNF20co5		SNCKKSLECT	KLCLPQIENV	KGTEDSGTTV	LLPLVIFFGL	~
TNF20co9		SNCKKSLECT	KLCLPQIENV	KGTEDSGTTV	LLPRVIFFGL	CLLSLLFI..
TNF19co1		SNCKKSLECT	KLCLPQIENV	KGTEDSGTTV	LLPLVIFFGL	CLLSLLFI..
TNF20co1		~	~	~	~	CLLSLLTSKA
TNF10-co9		~	~	~	~	~
TNF19co23		~	~	~	~	~
HUMTNFRB	251	..GLMYRYQR	WKSCLYSIVC	GKSTPEKEGE	LEGTTKPLA	300
TNF_10co8		~	~	~	~	PNPSFSPTPG
TNF20co5		..GLMYRYQR	WKSCLYSIVC	GKSTPEKEGE	LEGTTKPLV	~
TNF20co9		..GLMYRYQR	WKSCLYSIVC	GKSTPEKEGE	LEGTTKPLA	RP*~
TNF19co1		ARGPLVRP*~	~	~	~	PNPSFSPTPG
TNF20co1		~	~	~	~	~
TNF10-co9		~	~	~	~	~
TNF19co23		~	~	~	~	~

Fig. 1(Cont. <sup>2</sup>)

HUMTNFRB	FTPTLGFSPV	PSSTFTSSST	YTPGDCPNFA	APPREVAPPY	QGADPILATA	350
TNF_10co8	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF20co5	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF20co9	FTPTLGFSPV	PSSTFTSSKA	ARGPLVRP*	~~~~~	~~~~~	
TNF19co1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF20co1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF10-co9	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF19co23	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
HUMTNFRB	LASDPIPNPL	QKWEDSAHKP	QSLDTDDPAT	LYAVVENVPP	LRWKEFVRRL	400
TNF_10co8	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF20co5	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF20co9	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF19co1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF20co1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF10-co9	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
TNF19co23	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	

Fig. 1 (Cont. <sup>3</sup>)

401	HUMTNFRB	GLSDHEIDRL	ELQNGRCIRE	AQYSMLATWR	RRTPRREATL	ELLGRVLRDM	450
	TNF_10C08	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
	TNF20C05	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
	TNF20C09	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
	TNF19C01	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
	TNF20C01	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
	TNF10-C09	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
	TNF19C023	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	

**Fig. 1 (Cont. <sup>4</sup>)**



## DECLARATION FOR PATENT APPLICATION

Attorney Docket: 24286  
Page 1 of 2

As a below-named inventor(s), I/we hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) is/are as stated below next to my/our name(s).

I/We believe I/we am/are the original inventor, first and sole (*if only one name is listed below*) or the original, first and joint inventors (*if plural names are listed below*) of the subject matter which is claimed, and for which a patent is sought on the invention entitled:

**VARIANT OF TNF-RECEPTOR**

the specification of which: (check one)

☐ is attached hereto.

☐ was filed on \_\_\_\_\_, as Serial No. \_\_\_\_\_,

and was amended on \_\_\_\_\_ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability of this application as defined by 37 CFR § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

## Prior Foreign Applications:

			Priority Claimed	
<u>130608</u>	<u>ISRAEL</u>	<u>23 / June / 1999</u>	<input checked="" type="checkbox"/> [X]	<input type="checkbox"/> [ ]
(Application No.)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>	<input type="checkbox"/> [ ]	<input type="checkbox"/> [ ]
(Application No.)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>	<input type="checkbox"/> [ ]	<input type="checkbox"/> [ ]
(Application No.)	(Country)	(Day/Month/Year Filed)	Yes	No

We hereby appoint Gary M. Nath, Reg. No. 26,965; Harold L. Novick, Reg. No. 26,011; Todd L. Juneau, Reg. No. 40,669; Lee C. Heiman, Reg. No. 41,827; Jerald L. Meyer, Reg. No. 41,194; Joshua B. Goldberg, Reg. No. 44,126; David R. Murphy, Reg. No. 22,751; Paul A. Sacher, Reg. No. 43,418; Charles D. Niebylski, Reg. No. 46,116; Deborah H. Yellin, 45,904; Nahied K. Usman, Reg. No. P-47,148; and Roger Hahn, Reg. No. 46,376; as my attorneys to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct Telephone Calls to:

Gary M. Nath  
(202) 775-8383

Send Correspondence to:  
**NATH & ASSOCIATES PLLC**  
Sixth Floor  
1030 15<sup>th</sup> Street, N.W.  
Washington, D.C. 20005 U.S.A.

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by 35 U.S.C. § 112, first paragraph, I/we acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(U.S. Application Serial No.)	(U.S. Filing Date)	(Status--patented, pending, abandoned)
(U.S. Application Serial No.)	(U.S. Filing Date)	(Status--patented, pending, abandoned)

**DECLARATION FOR PATENT APPLICATION**Attorney Docket: 24286  
Page 2 of 2

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Kinneret SAVITZKY

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Metodela Street 44, Tel Aviv 69548, ISRAELCountry of Citizenship: ISRAELPost Office Address: Same as residenceFull name of second inventor: Amir TOPORIK

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Katznelson Street 20/2, Azur 58016, ISRAELCountry of Citizenship: ISRAELPost Office Address: Same as residenceFull name of third inventor: Sharon BITON

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Ilanot Street 71A, Herzliya 46565, ISRAELCountry of Citizenship: ISRAELPost Office Address: Same as residence

[illegible]

jc858 U.S. PRO  
09/599400  
06/22/00



```

ctgtccaggc cgggggcagg atacggactg cagggagtgt gagagcggct ccttcaccgc 300
ttcagaaaac cacctcagac actgcctcag ctgctccaaa tgccgaaagg aaatgggtca 360
gggtggagatc tcttcttgca cagtggaccg ggacaccgtg tgtggctgca ggaagaacca 420
gtaccggcat tattggagtg aaaacctttt ccagtgcctc aattgcagcc tctgcctcaa 480
tgggaccgtg cacctctcct gccaggagaa acagaacacc gtgtgcacct gccatgcagg 540
tttctttcta agagaaaacg agtgtgtctc ctgtagtaac tgtaagaaaa gcctggagtg 600
cacgaagtgt tgcctacccc agattgagaa tgtaagggtc actgaggact caggcaccac 660
agtgtgtgtg cccctggtea ttttctttgg tctttgcctt ttatccctcc tcttcattgg 720
tttaatgtat cgctaccaac ggtggaagtc caagctctac tccattgttt gtgggaaatc 780
gacacctgaa aaagaggggg agcttgaagg aactactact aagcccctgg ttcgtccctg 840
agcctttttc acagtgcata agcagttttt tttgtttttg tttgttttgt tttgttttta 900
aatcaatcat gttacactaa tagaaacttg gcactcctgt gccctctgcc tggacaagca 960
catagcaagc tgaactgtcc taaggcaggg gcgagcacgg aacaatgg 1008

```

<210> 3

<211> 1119

<212> DNA

<213> Homo sapiens

<400> 3

```

gggagtgaga ggccatagct gtctggcatg ggccctctcca ccgtgcctga cctgctgctg 60
ccgctggtgc tcctggagct gttggtggga atatacccct caggggttat tggactggtc 120
cctcacctag gggacaggga gaagagagat agtgtgtgtc cccaaggaaa atatatccac 180
cctcaaaata attcgatttg ctgtaccaag tgccacaaag gaacctactt gtacaatgac 240
tgtccaggcc cggggcaggga tacggactgc agggagtgtg agagcggttc cttcaccgct 300
tcagaaaacc acctcagaca ctgcctcagc tgctccaaat gccgaaagga aatgggtcag 360
gtggagatct cttcttgac agtggaccgg gacaccgtgt gtggctgcag gaagaaccag 420
taccggcatt attggagtga aaaccttttc cagtgcctca attgcagcct ctgcctcaat 480
gggaccgtgc acctctcctg ccaggagaaa cagaacaccg tgtgcacctg ccatgcaggc 540
ttctttctaa gagaaaacga gtgtgtctcc tgtagtaact gtaagaaaag cctggagtgc 600
acgaagtgtg gcctacccca gattgagaat gtaagggtca ctgaggactc aggcaccaca 660
gtgctgttgc cccgggtcat tttctttggt ctttgccttt taccctcct cttcattggc 720
ttaatgtatc gctaccaacg gtggaagtcc aagctctact ccattgtttg tgggaaatcg 780
acacctgaaa aagaggggga gcttgaagga actactacta agcccctggc cccaaaccca 840
agcttcagtc ccactccagg cttcaccccc accctgggct tcagtcctgt gccagttcc 900
accttcacct ccagcaaggc tgctcggggg ccctcggttc gtcctgagc ctttttcaca 960
gtgcataagc agtttttttt gtttttgttt tgttttgttt tgtttttaa teaatcatgt 1020
tacactaata gaaacttggc actcctgtgc cctctgcctg gacaagcaca tagcaagctg 1080
aactgtccta aggcaggggc gagcacggaa caatgggca 1119

```

<210> 4

<211> 918

<212> DNA

<213> Homo sapiens

<400> 4

```

gggagtgaga ggccatagct gtctggcatg ggcctctcca cctgcctga cctgctgctg 60
ccgctgggtgc tcctggagct gttgggtgga atataccct caggggttat tggactggtc 120
cctcacctag gggacagga gaagagagat agtgtgtgtc cccaaggaaa atatatccac 180
cctcaaaata attcgatttg ctgtaccaag tgccacaaag gaacctactt gtacaatgac 240
tgtccaggcc cggggcagga tacggactgc agggagtgtg agagcggtc cttcaccgct 300
tcagaaaacc acctcagaca ctgcctcagc tgctccaaat gccgaaagga aatgggtcag 360
gtggagatct cttcttgac agtggaccgg gacaccgtgt gtggctgacg gaagaaccag 420
taccggcatt attggagtga aaaccttttc cagtgttca attgcagcct ctgcctcaat 480
gggaccgtgc acctctcctg ccaggagaaa cagaacaccg tgtgcacctg ccatgcagggt 540
ttctttctaa gagaaaacga gtgtgtctcc tgtagtaact gtaagaaaag cctggagtgc 600
acgaagtgtg gcctacccca gattgagaat gtttaaggga ctgaggactc aggcaccaca 660
gtgctgttgc cctcggctat tttctttggt ctttgccttt tatccctcct caccagcaag 720
gctgctcggg ggccctcgtt tcgtccctga gcctttttca cagtgcataa gcagtttttt 780
ttgtttttgt tttgttttgt tttgttttta aatcaatcat gttactacta tagaaacttg 840
gcactcctgt gccctctgcc tggacaagca catagcaagc tgaactgtcc taaggcaggg 900
gcgagcacgg aacaatgg                                     918

```

<210> 5

<211> 542

<212> DNA

<213> Homo sapiens

<400> 5

```

gggagtgaga ggcctagctg tctggcatgg gcctctccac cgtgcctgac ctgctgctgc 60
cgctgggtgct cctggagctg ttgggtggga tataccctc aggggttatt ggactgggtc 120
ctcacctagg ggacagggag aagagagata gtgtgtgtcc ccaaggaaaa tatatccacc 180
ctcaaaataa ttcgatttgc tgtaccaagt gccacaaagg aacctacttg tacaatgact 240
gtccaggccc ggggcaggat acggactgca gggagtgtga gagcggtcc ttcaccgctt 300
cagaaaacca cctcatgccc gttttgggtg tctcaccag caaggctgct cgggggcccc 360
tggttcgtcc ctgagccttt ttcacagtgc ataagcagtt ttttttgttt ttgttttgtt 420
ttgttttgtt tttaaatcaa tcattgtaca ctaatagaaa cttggcactc ctgtgccctc 480
tgcttgagca agcacatagc aagctgaact gtcttaaggc aggggcgagc acggaacaat 540
gg                                     542

```

<210> 6

<211> 714

<212> DNA

<213> Homo sapiens

<400> 6

```

ggagtgagag gccatagctg tctggcatgg gcctctccac cgtgcctgac ctgccgctgc 60
cactgattct tcccagggtg ctccctggagc tgttgggtgg aatatacccc tcaggggtta 120
ttggactggt cctcaccta ggggacaggg agaagagaga tagtgtgtgt cccaaggaa 180
aatatatcca cctcgggctt cagtcccgtg cccagtcttc tcagatgagg ctgcgccct 240
gcgggcagct ctaaggaccg tcctgcgaga tcgccttcca accccacttt tttctggaaa 300
ggaggggtcc tgcaggggca agcaggagct agcagccgcc tacttggtgc taaccctc 360

```

atgtacatag cttttctcag ctgcctgogc gccgccgaca gtcagcgctg tgcggcgga 420  
gagagggtgc cctggggctc aagagcctga gtgggtggtt tgcgaggatg agggacgcta 480  
tgcctcatgc ccttttggg tgtcctcacc agcaaggctg ctggggggcc cctggttcgt 540  
ccctgagcct ttttcacagt gcataagcag ttttttttgt ttttgtttg ttttgtttg 600  
tttttaaata aatcatgtta cactaataga aacttggcac tctgtgccc tctgcctgga 660  
caagcacata gcaagctgaa ctgtcctaag gcaggggcga gcacggaaca atgg 714

<210> 7

<211> 1132

<212> DNA

<213> Homo sapiens

<400> 7

ggggagttag aggccatagc tgtctggcat gggcctctcc accgtgcctg acctgctgct 60  
gccgtggtg ctccttcacc gcttcagaaa accacctcag acaactgcctc agctgctcca 120  
aatgccgaaa ggaaatgggt cagggtggaga tctcttcttg cacagtggac cgggacaccg 180  
tgtgtggctg caggaagaac cagtaccggc attattggag tgaaaacctt ttccagtgtc 240  
tcaattgcag cctctgcctc aatgggaccg tgcacctctc ctgccaggag aaacagaaca 300  
ccgtgtgcac ctgccatgca ggtttctttc taagagaaaa cgagtgtgtc tctgtagta 360  
actgtaagaa aagcctggag tgcacgaagt tgtgcctacc ccagattgag aatgttaagg 420  
gcactgagga ctcaggcacc acagtgtgtg tggcctggt cattttcttt ggtctttgcc 480  
ttttatccct cctcttcatt ggtttaatgt atcgtacca acggtggaag tccaagctct 540  
actccattgt ttgtgggaaa tcgacacctg aaaaagaggg ggagcttgaa ggaactacta 600  
ctaagccctt ggcccaaac ccaagcttca gtccactcc aggttcacc cccaccctgg 660  
gcttcagtcc cgtgcccagt tccaccttcg ccttccaacc ccactttttt ctggaaagga 720  
ggggtcctgc aggggcaagc aggagctagc agccgctac ttggtgctaa cccctcgatg 780  
tacatagctt ttctcagctg cctgcgcgcc gccgacagtc agcgctgtgc gcgcggagag 840  
agggtgcgcc tgggtcgaag agcctgagtg ggtggtttgc gaggatgagg gacgctatgc 900  
ctcatgccc ttttgggtgt cctcaccagc aaggctgtc gggggccctt ggttcgtccc 960  
tgagcctttt tcacagtga taagcagttt tttttgttt tgtttgttt tgtttgttt 1020  
ttaaatcaat catgttacac taatagaaac ttggcactcc tgtgccctct gcctggacaa 1080  
gcacatagca agctgaactg tctaaggca ggggcgagca cggaacaatg gg 1132

<210> 8

<211> 1316

<212> DNA

<213> Homo sapiens

<400> 8

cggccagtg atcttgaacc ccaaaggcca gaactggagc ctcagtccag agaattctga 60  
gaaaattaaa gcagagagga ggggagagat cactgggacc aggccgtgat ctctatgcc 120  
gagttcgaac cctcaactgt caccacaagg cacttgggac gtcttggaac gaccgagtc 180  
cgggaagccc cagcactgcc gctgccacac tgcctgagc ccaaatgggg gagtgaagg 240  
ccatagctgt ctggcatggg cctctccacc gtcttcacct ccagctccac ctatacccc 300  
ggtgactgtc ccaactttgc ggctccccgc agagaggtgg caccacccta tcagggggct 360  
gaccccatcc ttgcgacagc cctgcctcc gaccccatcc ccaacccctc tcagaagtgg 420

[illegible]

<211> 219

<213> Homo sapiens

Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu  
1 5 10 15

Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro  
20 25 30

His	Leu	Gly	Asp	Arg	Glu	Lys	Arg	Asp	Ser	Val	Cys	Pro	Gln	Gly	Lys
		35					40					45			

Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys  
50 55 60

Gly	Thr	Tyr	Leu	Tyr	Asn	Asp	Cys	Pro	Gly	Pro	Gly	Gln	Asp	Thr	Asp
65					70					75					80

Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu  
85 90 95

Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln Val  
100 105 110

Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg  
115 120 125

5

130

135

140

Asn Cys Ser Leu Cys Leu Asn Gly Thr Val His Leu Ser Cys Gln Glu  
 145 150 155 160

Lys Gln Asn Thr Val Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu  
 165 170 175

Asn Glu Cys Val Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr  
 180 185 190

Lys Leu Cys Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser  
 195 200 205

Gly Thr Thr Val Leu Leu Pro Leu Val Arg Pro  
 210 215

&lt;210&gt; 10

&lt;211&gt; 270

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu  
 1 5 10 15

Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro  
 20 25 30

His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro Gln Gly Lys  
 35 40 45

Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys  
 50 55 60

Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro Gly Gln Asp Thr Asp  
 65 70 75 80

Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu  
 85 90 95

Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln Val  
 100 105 110

Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg  
 115 120 125



Lys Asn Gln Tyr Arg His Tyr Trp Ser Glu Asn Leu Phe Gln Cys Phe  
130 135 140

Asn Cys Ser Leu Cys Leu Asn Gly Thr Val His Leu Ser Cys Gln Glu  
145 150 155 160

Lys Gln Asn Thr Val Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu  
165 170 175

Asn Glu Cys Val Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr  
180 185 190

Lys Leu Cys Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser  
195 200 205

Gly Thr Thr Val Leu Leu Pro Leu Val Ile Phe Phe Gly Leu Cys Leu  
210 215 220

Leu Ser Leu Leu Phe Ile Gly Leu Met Tyr Arg Tyr Gln Arg Trp Lys  
225 230 235 240

Ser Lys Leu Tyr Ser Ile Val Cys Gly Lys Ser Thr Pro Glu Lys Glu  
245 250 255

Gly Glu Leu Glu Gly Thr Thr Thr Lys Pro Leu Val Arg Pro  
260 265 270

<210> 11

<211> 306

<212> PRT

<213> Homo sapiens

<400> 11

Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu  
1 5 10 15

Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro  
20 25 30

His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro Gln Gly Lys  
35 40 45

Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys  
50 55 60

Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro Gly Gln Asp Thr Asp  
 65 70 75 80  
 Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu  
 85 90 95  
 Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln Val  
 100 105 110  
 Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg  
 115 120 125  
 Lys Asn Gln Tyr Arg His Tyr Trp Ser Glu Asn Leu Phe Gln Cys Phe  
 130 135 140  
 Asn Cys Ser Leu Cys Leu Asn Gly Thr Val His Leu Ser Cys Gln Glu  
 145 150 155 160  
 Lys Gln Asn Thr Val Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu  
 165 170 175  
 Asn Glu Cys Val Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr  
 180 185 190  
 Lys Leu Cys Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser  
 195 200 205  
 Gly Thr Thr Val Leu Leu Pro Arg Val Ile Phe Phe Gly Leu Cys Leu  
 210 215 220  
 Leu Ser Leu Leu Phe Ile Gly Leu Met Tyr Arg Tyr Gln Arg Trp Lys  
 225 230 235 240  
 Ser Lys Leu Tyr Ser Ile Val Cys Gly Lys Ser Thr Pro Glu Lys Glu  
 245 250 255  
 Gly Glu Leu Glu Gly Thr Thr Thr Lys Pro Leu Ala Pro Asn Pro Ser  
 260 265 270  
 Phe Ser Pro Thr Pro Gly Phe Thr Pro Thr Leu Gly Phe Ser Pro Val  
 275 280 285  
 Pro Ser Ser Thr Phe Thr Ser Ser Lys Ala Ala Arg Gly Pro Leu Val  
 290 295 300  
 Arg Pro  
 305

<210> 12  
 <211> 240  
 <212> PRT  
 <213> Homo sapiens

<400> 12

Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu  
 1 5 10 15

Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro  
 20 25 30

His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro Gln Gly Lys  
 35 40 45

Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys  
 50 55 60

Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro Gly Gln Asp Thr Asp  
 65 70 75 80

Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu  
 85 90 95

Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln Val  
 100 105 110

Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg  
 115 120 125

Lys Asn Gln Tyr Arg His Tyr Trp Ser Glu Asn Leu Phe Gln Cys Phe  
 130 135 140

Asn Cys Ser Leu Cys Leu Asn Gly Thr Val His Leu Ser Cys Gln Glu  
 145 150 155 160

Lys Gln Asn Thr Val Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu  
 165 170 175

Asn Glu Cys Val Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr  
 180 185 190

Lys Leu Cys Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser  
 195 200 205

Gly Thr Thr Val Leu Leu Pro Leu Val Ile Phe Phe Gly Leu Cys Leu

210

215

220

Leu Ser Leu Leu Thr Ser Lys Ala Ala Arg Gly Pro Leu Val Arg Pro  
 225 230 235 240

&lt;210&gt; 13

&lt;211&gt; 115

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu  
 1 5 10 15

Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro  
 20 25 30

His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro Gln Gly Lys  
 35 40 45

Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys  
 50 55 60

Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro Gly Gln Asp Thr Asp  
 65 70 75 80

Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu  
 85 90 95

Met Pro Val Leu Gly Val Leu Thr Ser Lys Ala Ala Arg Gly Pro Leu  
 100 105 110

Val Arg Pro  
 115

&lt;210&gt; 14

&lt;211&gt; 75

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

Met Gly Leu Ser Thr Val Pro Asp Leu Pro Leu Pro Leu Ile Leu Pro  
 1 5 10 15

Gln Val Leu Leu Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile  
 20 25 30

Gly Leu Val Pro His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys  
 35 40 45

Pro Gln Gly Lys Tyr Ile His Pro Gly Leu Gln Ser Arg Ala Gln Ser  
 50 55 60

Ser Gln Met Arg Leu Arg Pro Cys Gly Gln Leu  
 65 70 75

<210> 15  
 <211> 64  
 <212> PRT  
 <213> Homo sapiens

<400> 15  
 Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu  
 1 5 10 15

His Arg Phe Arg Lys Pro Pro Gln Thr Leu Pro Gln Leu Leu Gln Met  
 20 25 30

Pro Lys Gly Asn Gly Ser Gly Gly Asp Leu Phe Leu His Ser Gly Pro  
 35 40 45

Gly His Arg Val Trp Leu Gln Glu Glu Pro Val Pro Ala Leu Leu Glu  
 50 55 60

<210> 16  
 <211> 169  
 <212> PRT  
 <213> Homo sapiens

<400> 16  
 Met Gly Leu Ser Thr Val Phe Thr Ser Ser Ser Thr Tyr Thr Pro Gly  
 1 5 10 15

Asp Cys Pro Asn Phe Ala Ala Pro Arg Arg Glu Val Ala Pro Pro Tyr  
 20 25 30  
 Gln Gly Ala Asp Pro Ile Leu Ala Thr Ala Leu Ala Ser Asp Pro Ile  
 35 40 45  
 Pro Asn Pro Leu Gln Lys Trp Glu Asp Ser Ala His Lys Pro Gln Ser  
 50 55 60  
 Leu Asp Thr Asp Asp Pro Ala Thr Leu Tyr Ala Val Val Glu Asn Val  
 65 70 75 80  
 Pro Pro Leu Arg Trp Lys Glu Phe Val Arg Arg Leu Gly Leu Ser Asp  
 85 90 95  
 His Glu Ile Asp Arg Leu Glu Leu Gln Asn Gly Arg Cys Leu Arg Glu  
 100 105 110  
 Ala Gln Tyr Ser Met Leu Ala Thr Trp Arg Arg Arg Thr Pro Arg Arg  
 115 120 125  
 Glu Ala Thr Leu Glu Leu Leu Gly Arg Val Leu Arg Asp Met Asp Leu  
 130 135 140  
 Leu Gly Cys Leu Glu Asp Ile Glu Glu Ala Leu Cys Gly Pro Ala Ala  
 145 150 155 160  
 Leu Pro Pro Ala Pro Ser Leu Leu Arg  
 165